Generics and API Manufacturers Aurobindo and Lupin Slapped With Lengthy 483s

The FDA issued a 10-observation Form 483 to Aurobindo’s Telangana, India, plant after a November visit, outlining several violations of current good manufacturing practices (cGMP).
Source: Drug Industry Daily